CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Magnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

Defines coverage stance for laparoscopically implanted magnetic esophageal sphincter augmentation (LINX) for treatment of gastroesophageal reflux disease for Blue Cross Blue Shield - Rhode Island members.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyMagnetic Esophageal Sphincter Augmentation to Treat Gastroesophageal Reflux

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJan 1, 2017

Next Review DateN/A

Key ActionVerify member benefits and obtain prior authorization if required by the specific benefit plan.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredCoverage stance

43284CPT flagged

FDA approvedDevice status

2021-01-20Last update

Coverage Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Magnetic esophageal sphincter augmentation (eg, laparoscopically implanted magnetic band devices) is not covered under this policy. The policy states: "Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes."

For Commercial members the procedure is considered not medically necessary. As stated in the policy: "Magnetic esophageal sphincter augmentation to treat gastroesophageal reflux disease is not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes." This summarizes the evidence-based rationale used for commercial coverage determinations.

Provider Actions and Billing Impact

Prior Authorization

Verify Benefits and Prior Authorization

Benefits may vary by contract. Verify the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement prior to scheduling services.

Check member-specific benefits for coverage details
Obtain any required prior authorization before performing services

Step Therapy

Step Therapy Context

This policy does not establish coverage criteria for step therapy. The LINX device was FDA-approved for patients with GERD who continue to have chronic symptoms despite maximum medical therapy; step-therapy requirements (such as trials of high-dose PPIs) may apply per the member's contract.

Target population: patients with GERD despite maximum medical therapy
Policy statement: device/procedure is considered not medically necessary by this payer

Documentation Required

Verify Benefits and Eligibility

Verify the member's eligibility and benefit limitations in the Benefit Booklet/Subscriber Agreement. Obtain and document any required authorizations before rendering services to avoid claim denials.

Confirm eligibility and benefits prior to service date
Document authorization number on claims when required

Denial Risk

Denial Risk for CPT 43284

CPT 43284 (laparoscopy, esophageal sphincter augmentation; placement of sphincter augmentation device) is not medically necessary per this policy and claims may be denied if billed for members under plans that follow this policy.

Affected code: CPT 43284
Medicare Advantage Plans and Commercial: may be denied as not medically necessary

Clinical Background

Gastroesophageal reflux disease (GERD) is reflux of stomach acid into the esophagus causing symptoms and/or mucosal injury. Devices intended to augment the lower esophageal sphincter, such as magnetic esophageal sphincter augmentation systems, are designed to reduce reflux by mechanically augmenting the sphincter. However, per this policy the available evidence for these devices is insufficient to determine their effects on health outcomes, which informs the noncoverage and not medically necessary determinations.

Definitions

LINX device description

Device nameLINX Reflux Management System

DescriptionSmall flexible band of 10 to 18 interlinked titanium beads with magnetic cores placed laparoscopically around the esophagus to augment the lower esophageal sphincter.

PlacementPlaced around the esophagus at the level of the gastroesophageal junction using standard laparoscopic techniques.

MechanismMagnetic attraction between beads augments the lower esophageal sphincter to prevent reflux while allowing separation during swallowing.

RemovabilityDevice can be removed laparoscopically if severe adverse events occur or if MRI is needed.

GERD definition

DefinitionGastroesophageal reflux disease (GERD) — reflux of stomach acid into the esophagus causing symptoms and/or mucosal injury.

Clinical spectrumRanges from mild, intermittent symptoms to chronic, severe disease with complications such as Barrett esophagus and esophageal cancer.

Typical populationPatients with GERD symptoms despite maximal medical therapy (e.g., proton pump inhibitors) who may seek alternatives to lifelong medication or major surgery.

Common treatmentsMedical therapy with acid blockers (proton pump inhibitors) and surgical options such as Nissen fundoplication; less invasive procedures are evaluated as intermediate options.